Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial

NCT03406650 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03406650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03406650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2018
Completion date
January 31, 2025
Enrollment
61 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial cancer